(19)
(11) EP 3 298 043 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
21.04.2021 Bulletin 2021/16

(45) Mention of the grant of the patent:
30.12.2020 Bulletin 2020/53

(21) Application number: 16797166.2

(22) Date of filing: 17.05.2016
(51) International Patent Classification (IPC): 
C07K 14/705(2006.01)
C07K 16/28(2006.01)
A61P 7/06(2006.01)
A61P 11/06(2006.01)
A61P 35/00(2006.01)
A61P 37/06(2006.01)
A61P 43/00(2006.01)
C07K 14/55(2006.01)
A61K 38/20(2006.01)
A61P 9/10(2006.01)
A61P 31/12(2006.01)
A61P 37/02(2006.01)
A61P 37/08(2006.01)
(86) International application number:
PCT/US2016/032921
(87) International publication number:
WO 2016/187226 (24.11.2016 Gazette 2016/47)

(54)

SIRP POLYPEPTIDE COMPOSITIONS AND METHODS OF USE

SIRP-POLYPEPTID-ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG

COMPOSITIONS DE POLYPEPTIDE SIRP ET PROCÉDÉS D'UTILISATION


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 18.05.2015 US 201562163282 P
11.12.2015 US 201562266450 P

(43) Date of publication of application:
28.03.2018 Bulletin 2018/13

(60) Divisional application:
20216691.4

(73) Proprietor: AB Initio Biotherapeutics, Inc.
San Diego, CA 92121 (US)

(72) Inventors:
  • RING, Aaron Michael
    Palo Alto, California 94306 (US)
  • MAUTE, Roy Louis
    San Francisco, California 94103 (US)
  • KRUSE, Andrew Curtis
    Roslindale, Massachusetts 02131 (US)
  • MANGLIK, Aashish
    Menlo Park, California 94025 (US)
  • LIN, Kenneth S.
    Los Altos, California 94023 (US)

(74) Representative: Mewburn Ellis LLP 
Aurora Building Counterslip
Bristol BS1 6BX
Bristol BS1 6BX (GB)


(56) References cited: : 
US-A1- 2010 239 579
   
  • E SICK ET AL: "CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest", BRITISH JOURNAL OF PHARMACOLOGY, vol. 167, no. 7, 6 November 2012 (2012-11-06), pages 1415-1430, XP055247122, UK ISSN: 0007-1188, DOI: 10.1111/j.1476-5381.2012.02099.x
  • GARY BROOKE ET AL: "Human Lymphocytes Interact Directly with CD47 Through a Novel Member of the Signal Regulatory Protein (SIRP) Family", THE JOURNAL OF IMMUNO, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 173, no. 4, 15 August 2004 (2004-08-15), pages 2562-2570, XP008138739, ISSN: 0022-1767
  • JOANNE E NETTLESHIP ET AL: "Crystal structure of signal regulatory protein gamma (SIRP[gamma]) in complex with an antibody Fab frag", BMC STRUCTURAL BIOLOGY, BIOMED CENTRAL LTD., LONDON, GB, vol. 13, no. 1, 4 July 2013 (2013-07-04), page 13, XP021156553, ISSN: 1472-6807, DOI: 10.1186/1472-6807-13-13
  • HATHERLEY, D ET AL.: 'Paired Receptor Specificity Explained by Structures of Signal Regulatory Proteins Alone and Complexed with CD 47.' MOLECULAR CELL . vol. 31, no. 2, 25 July 2008, pages 266 - 277, XP055175089
  • LEE, WY ET AL.: 'Novel Structural Determinants on SIRP alpha that Mediate Binding to CD 47.' THE JOURNAL OF IMMUNOLOGY vol. 179, no. 11, 01 December 2007, pages 7741 - 7750, XP055081468
  • STEFANIDAKIS, M ET AL.: 'Endothelial CD 47 Interaction with SIRP gamma is Required for Human T- cell Transendothelial Migration Under Shear Flow Conditions In Vitro.' BLOOD vol. 112, no. 4, 04 June 2008, pages 1280 - 1289, XP055331545
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).